Background: Rikkunshito, one of the Kampo medicines, is widely prescribed as a rem-
anorexia, gastric dysmotility, and gastrointestinal (GI) symptoms such as postprandial fullness and epigastric pain [4] [5] [6] . Thus, rikkunshito is widely prescribed as a remedy for various upper GI syndromes.
In clinical studies 7, 8 and animal model experiments [9] [10] [11] [12] , the effects of endogenous ghrelin have been reported as the mechanism for these actions of rikkunshito. Ghrelin is a 28-amino acid peptide identified as a natural ligand for the growth hormone secretagogue-receptor (GHS-R) 13 . It is mainly secreted from X/A-like cells in the stomach in coordination with circadian rhythms in feeding behavior, and to some extent, secreted in the brain, and plays a role in eliciting feeding and augmenting GI motility via the gut-brain axis. Rikkunshito synergistically promotes endogenous ghrelin activity by regulating ghrelin secretion 9 , ghrelin receptor sensitization 10 , and ghrelin degradation 11 . The active ingredients of rikkunshito responsible for these effects have been identified 14 .
A recent clinical pharmacokinetic study has demonstrated that oral administration of rikkunshito in healthy volunteers increases the plasma concentration of several active ingredients in a dosedependent manner; atractylodin, in particular, is a major ingredient detected in the plasma 15 . In vitro studies have revealed that atractylodin increases the binding activity of ghrelin to GHS-R and sustains the increase in ghrelin-induced intracellular calcium ions or cyclic adenosine monophosphate in GHS-R-expressing cells, suggesting an enhancing activity of ghrelin receptor signaling 10, 16 . Thus, atractylodin might modify appetite or GI motility.
Although almost all Kampo medicines including rikkunshito are traditionally administered before or between meals in patients, there is no definitive proof yet for a benefit to the correct timing of administration. Thus, to clarify the influence of food on the pharmacological action of rikkunshito, we focused on the ghrelin receptor-stimulating action of atractylodin and investigated its effect on gastric motor activity and on the pharmacokinetic profile of rikkunshito after oral administration under fasted and fed conditions.
| MATERIALS AND METHODS

| Animals
Male Wistar rats weighing 200-250 g were purchased from Clea Japan (Tokyo, Japan). Seven-week-old male Sprague-Dawley (SD) rats were purchased from Charles River Laboratories Japan (Tokyo, Japan). They were housed in a regulated environment, with controlled conditions of ambient temperature (23±3°C), humidity (50±20%), and lighting (12-hour light:dark cycle). Animals were given free access to water and standard laboratory chow. All experimental procedures were performed according to the "Guidelines for the Care and 
| Reagent preparation
Ghrelin (acyl ghrelin, Peptide Institute, Osaka, Japan) was dissolved in saline. The Kampo medicine rikkunshito (Tsumura, Tokyo, Japan) Atractylodin (Wako, Osaka, Japan), an active ingredient of rikkunshito, was dissolved in a solution of 0.1% ethanol and 1% Tween-80.
| Animal preparation
We used male Wistar rat for motility index examination as described previously 17 . Overnight fasted rats were anesthetized with sodium pentobarbital (50 mg kg 
| Measurement of gastric motility
The connector of the strain gauge force transducer placed in the fasted rats was connected to an FS-04M preamplifier (Star Medical, Inc.) via an FB-01 bridge box (Star Medical, Inc.) to allow measurement of movement of the antrum. Data were recorded using an MP150
(BIOPAC Systems, CA, USA). The system was calibrated before each experiment using a calibrator (Star Medical, Inc.), and contractions were expressed in grams.
Key Points
• Rikkunshito is used for various upper gastrointestinal syndromes and known to promote endogenous ghrelin activity. This study aims to investigate the influence of food and timing of administration on the pharmacological action of rikkunshito.
• Rikkunshito administration potentiated ghrelin-induced gastric motor activity in fasted rats. Plasma and brain levels of atractylodin, an active ingredient of rikkunshito, increased more and more rapidly in fasted than in free-fed rats.
• The efficacy of rikkunshito may be associated with decreased absorption of atractylodin when food is in the stomach. To assess the efficacy of rikkunshito administration in the postprandial period, fasted rats were gavaged with a nutrient test meal , n=7) or distilled water (n=7).
| Experimental protocols
| Time-course plasma sampling and pharmacokinetic analysis
For the pharmacokinetic study, we used male SD rat in an international genetic standardized colony. A vessel catheter was inserted into the right jugular vein in rats under isoflurane anesthesia. After recovering for 1 week after the operation, 16-hour fasted rats (n=7) and free-fed rats (n=6) were orally administered 1000 mg kg −1 of rikkunshito. Blood samples (0.5 mL) were collected through the catheter from the same animal 0, 0.25, 0.5, 1, 2, 4, and 8 hours after treatment with rikkunshito. After the blood samples were heparinized and centrifuged (3000 rpm, 15 minutes, 4°C), plasma samples were collected and stored at −80°C until use.
The level of atractylodin in plasma samples was determined according to a slight modification of the previously reported method 15 .
The plasma samples (250 μL) were mixed with 12.5 μL of methanol.
Subsequently, diethyl ether (3 mL) was added to the solutions, followed by shaking and centrifugation (3000 rpm, 5 minutes, 4°C).
The supernatant was dried at 25°C under a stream of nitrogen gas.
Subsequently, acetonitrile (200 μL) was added to the dried samples, followed by mixing and sonicating. The solutions were filtrated (0.22 μm; Millipore Corporation, Billerica, MA, USA) and centrifuged (10,000 rpm, 2 minutes, 4°C). The sample (1 μL) was injected into a gas chromatography-mass spectrometry (GC-MS) instrument, which consisted of an HP6890 series gas chromatograph connected to an 
| Brain sampling and pharmacokinetics analysis
Sixteen-h fasted rats (n=5) and free-fed rats (n=5) were orally admin- Brain pharmacokinetic data were analyzed by non-compartmental modeling using Phoenix WinNonlin (version 6.4, Certara L.P., St. Louis, MO, USA) to determine C max , t max , and AUC last . 
| Statistical analysis
| RESULTS
| Effects of rikkunshito and atractylodin on ghrelin-induced gastric motility
In fasted rats, the gastric motility was observed to consist of cyclic changes in contraction waves, which included a quiescent period (phase I-like contractions) followed by a group of contractions (phase III-like contractions), as reported in our previous study 17 .
When ghrelin (3 nmol) was intravenously administered through the vessel catheter to fasted rats in a quiescent period, phase III-like 
| Influence of food on plasma concentration of atractylodin after oral administration of rikkunshito
To determine the time-dependent change in plasma atractylodin levels, plasma samples were collected from the same rat using catheter at each time point following rikkunshito administration (1000 mg kg −1 ).
In fasted rats, the plasma atractylodin concentration increased more and more rapidly than that in free-fed rats ( Figure 4 , Table 1 ). C max was 2.4 times greater than and t max was one-fourth of that in free-fed rats (P<.001 and P<.05 respectively). However, there was no statistically significant difference in AUC last between the free-fed and fasted groups (P=.71).
| Distribution of atractylodin in the brain after oral administration of rikkunshito
To determine the distribution of atractylodin in the brain, brain samples were collected by decapitation from fasted and free-fed rats at various time intervals after the administration of rikkunshito (1000 mg kg −1 ). Atractylodin was detected in the brains of both fasted and free-fed rats. But the concentration increased more rapidly in fasted than in free-fed rats, and a significant difference was observed at 0.25 hour following rikkunshito administration, which was the t max of plasma atractylodin in the fasted rats (fasted, 28.2±1.0 vs free-fed, 7.5±1.1 ng g −1 brain; P<.001; Figure 5 ). Table 2 shows the pharmacokinetic parameters of brain atractylodin.
| DISCUSSION
In this study, we showed that the administration of rikkunshito and its active ingredient atractylodin to rats potentiates the phase III-like contractions induced by ghrelin treatment. This pharmacological effect of rikkunshito was more remarkable in fasted rats than that in rats administered a test meal. Moreover, we showed that atractylodin increases immediately in the plasma and brain of fasted rats, as compared to free-fed rats, after oral administration of rikkunshito.
These results suggest that maintaining appropriate levels of its active ingredient atractylodin is important for eliciting a significant effect of rikkunshito, and that food in the stomach influences the effect of rikkunshito by delaying the absorption of atractylodin.
It is well known that ghrelin is involved in motor activities of the upper GI tract in physiologically fasted subjects 19 . Phase III-like contractions in the gastroduodenum, which are fasted motor activities, are induced by endogenous ghrelin secretion 17, 19 . In this study, ghrelin administration immediately induced the phase III-like contractions both in the fasted and fed rats, which is consistent with previous studies 17, 18 . However, the difference in magnitudes between the fasted and postprandial phases remains unclear. In this study, because no significant difference in %MI was observed between both phases following ghrelin administration, it is considered that same degree of effect of ghrelin on the phase III-like contractions was observed between both phases within the doses or timings of ghrelin administration used.
Rikkunshito has been proven to increase ghrelin/GHS-R binding activity and enhance the increase in cytosolic calcium ions elicited by ghrelin in GHS-R-expressing cells 10 . In the present study, the ghrelininduced phase III-like contractions were potentiated in fasted rats by the administration of rikkunshito. The potentiating effect of rikkunshito on ghrelin reactivity in animal models with gastric dysmotility was observed in our previous report 20 . These findings suggest that these motor effects of rikkunshito are related to the increase in ghrelin receptor sensitization 10, 20 . Rikkunshito stimulates ghrelin secretion, and it is possible that a negative feedback mechanism of ghrelin secretion suppresses the phase III contraction induced by exogenous ghrelin administration. However, our results suggest that any negative influence is overcome by the activation of the ghrelin receptor by rikkunshito.
Atractylodin is the active ingredient predominantly detected in the plasma of healthy volunteers in a clinical pharmacokinetic study of rikkunshito 15 . The administration of rikkunshito to fasted rats immediately increased the actractylodin concentration in plasma, and the maximum concentration was reached at 15 minutes in this study. The ) increased the motility index compared to that of rats administered with distilled water (DW). However, there was no significant difference in the motility index between the rats pretreated with RKT and DW 30 minutes after ingestion of test meal. Data are expressed as mean±SE (n=7). *P<.05 (Tukey-Kramer test) administration of atractylodin also potentiated the gastric motility in rats at 30 minutes, which is almost completely consistent with the time till reaching peak levels of actractylodin in plasma after the administration of rikkunshito. Atractylodin has also been demonstrated to possess an enhancing effect on ghrelin receptor signaling 10 . Therefore, it seems likely that the augmentation of ghrelin-induced motility in the antrum after the administration of rikkunshito is mediated by an increase in ghrelin receptor signaling by the active ingredient atractylodin.
The motor effect of rikkunshito was more significant in rats administered with it during fasting than after test meal ingestion by gavage.
Food in the stomach is known to influence the bioavailability of various medicines 21 . Therefore, a pharmacokinetic study of rikkunshito in free-fed and fasted rats was conducted. The administration of rikkunshito under the fasted condition significantly shortened t max and increased C max of atractylodin compared to that under the fed condition.
It is common for the rate of absorption of drugs to be slower when taken with meals than during fasting because of decreased gastric emptying 21 . According to our previous reports, atractylodin could not be absorbed through the stomach 10 . In addition, it is considered that ≥30% of the test meal remained in the stomach 20, 22 when rikkunshito was administered. Therefore, it is suggested that food in the stomach suppressed the increased plasma concentration of atractylodin. The , po, B) was administered to fasted rats and the ghrelininduced gastric motility was compared with that after the first ghrelin administration. The motility index (C) was increased by pretreatment with atractylodin, compared to vehicle, in fasted rats. Data are expressed as mean±SE (n=7). *P<.05 (Student's t test) difference in C max of atractylodin could potentially affect the pharmacological effect of rikkunshito on the motility index in the antrum.
Meanwhile, there was no significant difference in AUC last between the fasted and fed rats. GHS-R, which is the site of action of atractylodin, is present in gastric submucosa. Although we did not measure atractylodin levels in gastric mucosa, they might be important, in addition to those in the plasma, for the enhancing effect of rikkunshito on gastric motility. Moreover, the absorption of atractylodin may vary according to the composition of test meal. Therefore, future studies are needed.
GHS-R is expressed on the termini of the afferent vagus nerves in the stomach and transmits ghrelin's signal to the brain 18, 23, 24 . Moreover, GHS-R is reportedly expressed in the brain, e.g, in the neuropeptide Y (NPY) neurons of the hypothalamic arcuate nucleus, and the intracerebroventricular injection of ghrelin enhances appetite and GI motility 18, 25 .
Possibly, atractylodin acts not only in the periphery but also in the brain.
However, the transport of atractylodin into the brain after the administration of rikkunshito has not been studied. We therefore investigated the pharmacokinetic profiles of atractylodin in the brain and in plasma.
We found that atractylodin is delivered to the brain after the oral administration of rikkunshito. Our preliminary examination demonstrated that atractylodin was also distributed in hypothalamus wherein NPY neurons are located. Because of the low detection sensitivity of atractylodin, we measured its levels in whole brain. Our findings suggest that atractylodin is transported into the brain wherein it elicits these effects.
Atractylodin carboxylate, a metabolite of atractylodin, could be identified in the plasma after the administration of rikkunshito in a study of healthy humans 15 . Like atractylodin, the metabolite increased the ghrelin/GHS-R binding activity in GSH-R-expressing cells 15 , suggesting that it contributes to the ghrelin signal-enhancing activity of rikkunshito. However, the details of this action in vivo remain unclear.
Whether the metabolite of atractylodin is involved in the gastric motor effect of rikkunshito should be determined in a future study.
In conclusion 
